Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

The role of inflammation in diabetic eye disease.

Mesquida M, Drawnel F, Fauser S.

Semin Immunopathol. 2019 Jun 7. doi: 10.1007/s00281-019-00750-7. [Epub ahead of print] Review.

PMID:
31175392
2.

Predictors for functional and anatomic outcomes in macular edema secondary to non-infectious uveitis.

Matas J, Llorenç V, Fonollosa A, Esquinas C, Diaz-Valle D, Berasategui B, Mesquida M, Artaraz J, Rios J, Adan A.

PLoS One. 2019 Jan 24;14(1):e0210799. doi: 10.1371/journal.pone.0210799. eCollection 2019.

3.

Anti-IL6-Receptor Tocilizumab in Refractory and Noninfectious Uveitic Cystoid Macular Edema: Multicenter Study of 25 Patients.

Vegas-Revenga N, Calvo-Río V, Mesquida M, Adán A, Hernández MV, Beltrán E, Valls Pascual E, Díaz-Valle D, Díaz-Cordovés G, Hernandez-Garfella M, Martínez-Costa L, Calvo I, Atanes A, Linares LF, Modesto C, González-Vela C, Demetrio-Pablo R, Aurrecoechea E, Cordero M, Domínguez-Casas LC, Atienza-Mateo B, Martín-Varillas JL, Loricera J, Palmou-Fontana N, Hernández JL, González-Gay MA, Blanco R.

Am J Ophthalmol. 2019 Apr;200:85-94. doi: 10.1016/j.ajo.2018.12.019. Epub 2019 Jan 17.

PMID:
30660771
4.

Antituberculous Treatment Itself Might Prevent Visual Impairment in Presumed Tuberculosis-Related Uveitis.

Llorenç V, Benejam G, Mesquida M, Sainz de la Maza M, Molins B, Alba C, Pelegrin L, Martínez JA, Adán A.

Ocul Immunol Inflamm. 2018 Nov 5:1-8. doi: 10.1080/09273948.2018.1541326. [Epub ahead of print]

PMID:
30395738
5.

Successful Optimization of Adalimumab Therapy in Refractory Uveitis Due to Behçet's Disease.

Martín-Varillas JL, Calvo-Río V, Beltrán E, Sánchez-Bursón J, Mesquida M, Adán A, Hernandez MV, Garfella MH, Pascual EV, Martínez-Costa L, Sellas-Fernández A, Cordero-Coma M, Díaz-Llopis M, Gallego R, Salom D, Ortego N, García-Serrano JL, Callejas-Rubio JL, Herreras JM, García-Aparicio Á, Maíz O, Blanco A, Torre I, Díaz-Valle D, Pato E, Aurrecoechea E, Caracuel MA, Gamero F, Minguez E, Carrasco-Cubero C, Olive A, Vázquez J, Ruiz-Moreno O, Manero J, Muñoz-Fernández S, Martinez MG, Rubio-Romero E, Toyos-Sáenz de Miera FJ, López Longo FJ, Nolla JM, Revenga M, González-Vela C, Loricera J, Atienza-Mateo B, Demetrio-Pablo R, Hernández JL, González-Gay MA, Blanco R.

Ophthalmology. 2018 Sep;125(9):1444-1451. doi: 10.1016/j.ophtha.2018.02.020. Epub 2018 Mar 27. Erratum in: Ophthalmology. 2019 Jan;126(1):177.

PMID:
29602570
6.

Reply.

Mesquida M, Llorenc V, Adan A.

Med Clin (Barc). 2018 Oct 23;151(8):336-337. doi: 10.1016/j.medcli.2018.02.005. Epub 2018 Mar 7. English, Spanish. No abstract available.

PMID:
29525112
7.

Golimumab in refractory uveitis associated to juvenile idiopathic arthritis: multicentre study of 7 cases and literature review.

Palmou-Fontana N, Calvo-Río V, Martín-Varillas JL, Fernández-Díaz C, Mesquida M, Adán A, Hernández MV, Cordero-Coma M, Maiz Alonso O, Díaz-Valle D, Fernández-Cid C, Ruiz-Moreno O, Hernández JL, González-Gay MA, Blanco R.

Clin Exp Rheumatol. 2018 Jul-Aug;36(4):652-657. Epub 2017 Dec 15. Review.

8.

Targeting interleukin-6 in autoimmune uveitis.

Mesquida M, Molins B, Llorenç V, de la Maza MS, Adán A.

Autoimmun Rev. 2017 Oct;16(10):1079-1089. doi: 10.1016/j.autrev.2017.08.002. Epub 2017 Aug 2. Review.

PMID:
28778705
9.

New imaging techniques in retinal vasculitis.

Mesquida M, Llorens V, Adán A.

Med Clin (Barc). 2017 Sep 20;149(6):261-266. doi: 10.1016/j.medcli.2017.05.009. Epub 2017 Jul 5. Review. English, Spanish.

PMID:
28687121
10.

TWENTY-FOUR MONTH FOLLOW-UP OF TOCILIZUMAB THERAPY FOR REFRACTORY UVEITIS-RELATED MACULAR EDEMA.

Mesquida M, Molins B, Llorenç V, Hernández MV, Espinosa G, Sainz de la Maza M, Adán A.

Retina. 2018 Jul;38(7):1361-1370. doi: 10.1097/IAE.0000000000001690.

PMID:
28520640
11.

Bacillus Calmette-Guérin Infection and Cytotoxicity in the Retinal Pigment Epithelium.

Llorenç V, Mesquida M, Molins B, González-Martín J, Sainz de la Maza M, Adán A.

Ocul Immunol Inflamm. 2018;26(5):786-792. doi: 10.1080/09273948.2016.1265655. Epub 2016 Dec 23.

PMID:
28010156
12.

C-reactive protein isoforms differentially affect outer blood-retinal barrier integrity and function.

Molins B, Pascual A, Méndez, Llorenç V, Zarranz-Ventura J, Mesquida M, Adán A, Martorell J.

Am J Physiol Cell Physiol. 2017 Mar 1;312(3):C244-C253. doi: 10.1152/ajpcell.00057.2016. Epub 2016 Dec 21.

13.

The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet's disease: results of a multicentre open-label study.

Santos-Gómez M, Calvo-Río V, Blanco R, Beltrán E, Mesquida M, Adán A, Cordero-Coma M, García-Aparicio ÁM, Valls Pascual E, Martínez-Costa L, Hernández MV, Hernandez Garfella M, González-Vela MC, Pina T, Palmou-Fontana N, Loricera J, Hernández JL, González-Gay MA.

Clin Exp Rheumatol. 2016 Sep-Oct;34(6 Suppl 102):S34-S40. Epub 2016 Apr 7.

PMID:
27054359
14.

Anti-Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis Refractory to Anti-Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty-Five Patients.

Calvo-Río V, Santos-Gómez M, Calvo I, González-Fernández MI, López-Montesinos B, Mesquida M, Adán A, Hernández MV, Maíz O, Atanes A, Bravo B, Modesto C, Díaz-Cordovés G, Palmou-Fontana N, Loricera J, González-Vela MC, Demetrio-Pablo R, Hernández JL, González-Gay MA, Blanco R.

Arthritis Rheumatol. 2017 Mar;69(3):668-675. doi: 10.1002/art.39940.

15.

Evidence for Tocilizumab as a Treatment Option in Refractory Uveitis Associated with Juvenile Idiopathic Arthritis.

Tappeiner C, Mesquida M, Adán A, Anton J, Ramanan AV, Carreno E, Mackensen F, Kotaniemi K, de Boer JH, Bou R, de Vicuña CG, Heiligenhaus A.

J Rheumatol. 2016 Dec;43(12):2183-2188. Epub 2016 Sep 15.

PMID:
27633821
16.

In Response to: "Deuter CM, Zierhut M, Igney-Oertel A, et al. Tocilizumab in Uveitic Macular Edema Refractory to Previous Immunomodulatory Treatment".

Mesquida M, Llorenç V, Adán A.

Ocul Immunol Inflamm. 2017 Apr;25(2):221-222. doi: 10.3109/09273948.2016.1145240. Epub 2016 Mar 25. No abstract available.

PMID:
27014943
17.

Interleukin-22 serum levels are elevated in active scleritis.

Sainz-de-la-Maza M, Molins B, Mesquida M, Llorenç V, Zarranz-Ventura J, Sala-Puigdollers A, Matas J, Adan A, Foster CS.

Acta Ophthalmol. 2016 Sep;94(6):e395-9. doi: 10.1111/aos.13005. Epub 2016 Mar 24.

18.

Elevated Serum Immune Mediators and Subclinical Inflammation in HLA-A29-associated Birdshot Chorioretinopathy.

Molins B, Mesquida M, Llorenç V, Sainz de la Maza M, Adán A.

Ocul Immunol Inflamm. 2016 Dec;24(6):647-652. Epub 2015 Dec 8.

PMID:
26645126
19.

Anti-TNF-α therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients.

Riancho-Zarrabeitia L, Calvo-Río V, Blanco R, Mesquida M, Adan AM, Herreras JM, Aparicio Á, Peiteado-Lopez D, Cordero-Coma M, García Serrano JL, Ortego-Centeno N, Maíz O, Blanco A, Sánchez-Bursón J, González-Suárez S, Fonollosa A, Santos-Gómez M, González-Vela C, Loricera J, Pina T, González-Gay MA.

Semin Arthritis Rheum. 2015 Dec;45(3):361-8. doi: 10.1016/j.semarthrit.2015.05.010. Epub 2015 May 21.

PMID:
26092330
20.

Uveitic macular oedema after treatment with vemurafenib.

Fonollosa A, Mesquida M, Adan A.

Acta Ophthalmol. 2015 Dec;93(8):e686-7. doi: 10.1111/aos.12678. Epub 2015 Feb 13. No abstract available.

21.

Epidemiology of uveitis in a Western urban multiethnic population. The challenge of globalization.

Llorenç V, Mesquida M, Sainz de la Maza M, Keller J, Molins B, Espinosa G, Hernandez MV, Gonzalez-Martín J, Adán A.

Acta Ophthalmol. 2015 Sep;93(6):561-7. doi: 10.1111/aos.12675. Epub 2015 Feb 15.

22.

Regulatory T cell levels and cytokine production in active non-infectious uveitis: in-vitro effects of pharmacological treatment.

Molins B, Mesquida M, Lee RW, Llorenç V, Pelegrín L, Adán A.

Clin Exp Immunol. 2015 Mar;179(3):529-38. doi: 10.1111/cei.12479.

23.

Certolizumab Pegol, a New Anti-TNF-α in the Armamentarium against Ocular Inflammation.

Llorenç V, Mesquida M, Sainz de la Maza M, Blanco R, Calvo V, Maíz O, Blanco A, de Dios-Jiménez de Aberásturi JR, Adán A.

Ocul Immunol Inflamm. 2016;24(2):167-72. doi: 10.3109/09273948.2014.967779. Epub 2014 Oct 17.

PMID:
25325834
24.

Long-term effects of tocilizumab therapy for refractory uveitis-related macular edema.

Mesquida M, Molins B, Llorenç V, Sainz de la Maza M, Adán A.

Ophthalmology. 2014 Dec;121(12):2380-6. doi: 10.1016/j.ophtha.2014.06.050. Epub 2014 Sep 6.

PMID:
25204610
25.

Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.

Calvo-Río V, Blanco R, Beltrán E, Sánchez-Bursón J, Mesquida M, Adán A, Hernandez MV, Hernandez Garfella M, Valls Pascual E, Martínez-Costa L, Sellas-Fernández A, Cordero Coma M, Díaz-Llopis M, Gallego R, Salom D, García Serrano JL, Ortego N, Herreras JM, Fonollosa A, García-Aparicio AM, Maíz O, Blanco A, Torre I, Fernández-Espartero C, Jovani V, Peiteado-Lopez D, Pato E, Cruz J, Fernández-Cid C, Aurrecoechea E, García M, Caracuel MA, Montilla C, Atanes A, Hernandez FF, Insua S, González-Suárez S, Sánchez-Andrade A, Gamero F, Linares L, Romero-Bueno F, García AJ, Almodovar R, Minguez E, Carrasco Cubero C, Olive A, Vázquez J, Ruiz Moreno O, Jiménez-Zorzo F, Manero J, Muñoz Fernández S, Rueda-Gotor J, González-Gay MA.

Rheumatology (Oxford). 2014 Dec;53(12):2223-31. doi: 10.1093/rheumatology/keu266. Epub 2014 Jul 4.

PMID:
24996907
26.

Proinflammatory cytokines and C-reactive protein in uveitis associated with Behçet's disease.

Mesquida M, Molins B, Llorenç V, Sainz de la Maza M, Hernandez MV, Espinosa G, Adán A.

Mediators Inflamm. 2014;2014:396204. doi: 10.1155/2014/396204. Epub 2014 Jun 8.

27.

Golimumab as rescue therapy for refractory immune-mediated uveitis: a three-center experience.

Cordero-Coma M, Calvo-Río V, Adán A, Blanco R, Álvarez-Castro C, Mesquida M, Calleja S, González-Gay MA, Ruíz de Morales JG.

Mediators Inflamm. 2014;2014:717598. doi: 10.1155/2014/717598. Epub 2014 May 28.

28.

Use of ultra-wide-field retinal imaging in the management of active Behçet retinal vasculitis.

Mesquida M, Llorenç V, Fontenla JR, Navarro MJ, Adán A.

Retina. 2014 Oct;34(10):2121-7. doi: 10.1097/IAE.0000000000000197.

PMID:
24946103
29.

Interleukin-6 blockade in ocular inflammatory diseases.

Mesquida M, Leszczynska A, Llorenç V, Adán A.

Clin Exp Immunol. 2014 Jun;176(3):301-9. doi: 10.1111/cei.12295. Review.

30.

[Retinal vasculopathy in systemic lupus erythematosus: a case of lupus vasculitis and a case of non-vasculitis venous occlusion].

Figueras-Roca M, Rey A, Mesquida M, Pelegrín L, Llorens V, Fontenla JR, Adán A.

Arch Soc Esp Oftalmol. 2014 Feb;89(2):66-9. doi: 10.1016/j.oftal.2012.06.030. Epub 2012 Oct 8. Spanish.

PMID:
24269411
31.

Tocilizumab for retinal vasoproliferative tumor secondary to juvenile idiopathic arthritis-associated uveitis: a case report.

Adán A, Mesquida M, Llorenç V, Modesto C.

Graefes Arch Clin Exp Ophthalmol. 2014 Jan;252(1):163-4. doi: 10.1007/s00417-013-2466-5. Epub 2013 Sep 24. No abstract available.

PMID:
24061910
32.

Tocilizumab treatment for refractory uveitis-related cystoid macular edema.

Adán A, Mesquida M, Llorenç V, Espinosa G, Molins B, Hernández MV, Pelegrín L.

Graefes Arch Clin Exp Ophthalmol. 2013 Nov;251(11):2627-32. doi: 10.1007/s00417-013-2436-y. Epub 2013 Jul 27.

PMID:
23893042
33.

Cytokine profiling reveals decreased serum levels of CCL2 in active ocular toxoplasmosis.

Rey A, Molins B, Llorenç V, Pelegrín L, Mesquida M, Adán A.

Br J Ophthalmol. 2013 Oct;97(10):1338-42. doi: 10.1136/bjophthalmol-2013-303092. Epub 2013 Jul 22.

PMID:
23878135
34.

Late spectral-domain optical coherence tomography findings in sub-internal limiting membrane hemorrhage.

Rey A, Adán A, Llorenç V, Pelegrín L, Mesquida M.

Retin Cases Brief Rep. 2013 Summer;7(3):276-7. doi: 10.1097/ICB.0b013e31828eefbd.

PMID:
25391123
35.

Current and future treatments for Behçet's uveitis: road to remission.

Mesquida M, Molins B, Llorenç V, Hernández MV, Espinosa G, Dick AD, Adán A.

Int Ophthalmol. 2014 Apr;34(2):365-81. doi: 10.1007/s10792-013-9788-5. Epub 2013 Jun 1. Review.

PMID:
23729309
36.

Clinical pattern of toxoplasmic retinochoroiditis in a Spanish referral center.

Rey A, Llorenç V, Pelegrín L, Mesquida M, Molins B, Rios J, Arévalo JF, Adán A.

Ophthalmologica. 2013;229(3):173-8. doi: 10.1159/000348740. Epub 2013 Mar 27.

PMID:
23548496
37.

Dexamethasone intravitreal implant for treatment of uveitic persistent cystoid macular edema in vitrectomized patients.

Adán A, Pelegrín L, Rey A, Llorenç V, Mesquida M, Molins B, Ríos J, Keller J.

Retina. 2013 Jul-Aug;33(7):1435-40. doi: 10.1097/IAE.0b013e31827e247b.

PMID:
23514796
38.

Adalimumab in serpiginous choroiditis.

Llorenç V, Molins B, Rey A, Mesquida M, Adán A.

Ocul Immunol Inflamm. 2013 Jun;21(3):237-40. doi: 10.3109/09273948.2012.761240. Epub 2013 Mar 12. No abstract available.

PMID:
23480603
39.

Tocilizumab treatment for recalcitrant uveitic macular edema.

Adán A, Llorenç V, Mesquida M, Pelegrín L.

Graefes Arch Clin Exp Ophthalmol. 2013 Sep;251(9):2249-50. doi: 10.1007/s00417-012-2243-x. Epub 2012 Dec 28. No abstract available.

PMID:
23271335
40.

Behçet disease-associated uveitis successfully treated with golimumab.

Mesquida M, Victoria Hernández M, Llorenç V, Pelegrín L, Espinosa G, Dick AD, Adán A.

Ocul Immunol Inflamm. 2013 Apr;21(2):160-2. doi: 10.3109/09273948.2012.741744. Epub 2012 Dec 19.

PMID:
23252659
41.

Pars plana vitrectomy for vitreoretinal complications of Behçet uveitis.

Mesquida M, Pelegrín L, Llorenç V, Espinosa G, Ríos J, Dick AD, Adán A.

Eur J Ophthalmol. 2013 Jan 21;23(1):119 - 128. doi: 10.5301/ejo.5000194. Epub 2012 Sep 26.

PMID:
23065857
42.

Indirect supportive evidence for diagnosis of tuberculosis-related uveitis: from the tuberculin skin test to the new interferon gamma release assays.

Llorenç V, González-Martin J, Keller J, Rey A, Pelegrín L, Mesquida M, Adán A.

Acta Ophthalmol. 2013 Mar;91(2):e99-e107. doi: 10.1111/j.1755-3768.2012.02564.x. Epub 2012 Oct 8.

43.

[Central nervous system demyelinating disease-associated uveitis].

Llorenç V, Rey A, Mesquida M, Pelegrín L, Adán A.

Arch Soc Esp Oftalmol. 2012 Oct;87(10):324-9. doi: 10.1016/j.oftal.2012.04.027. Epub 2012 Jul 20. Spanish.

PMID:
23021230
44.

[Ocular brucellosis].

Mesquida M, Llorenç V, Cervera C, Adán A.

Med Clin (Barc). 2013 Mar 16;140(6):284. doi: 10.1016/j.medcli.2012.07.008. Epub 2012 Sep 17. Spanish. No abstract available.

PMID:
22995842
45.

Adalimumab for the treatment of Behçet's disease: experience in 19 patients.

Perra D, Alba MA, Callejas JL, Mesquida M, Ríos-Fernández R, Adán A, Ortego N, Cervera R, Espinosa G.

Rheumatology (Oxford). 2012 Oct;51(10):1825-31. Epub 2012 Jun 20.

PMID:
22723596
46.

Blind runner.

Pelegrín L, Mesquida M, Rey A, Sánchez-Dalmau B, Frohman L.

Surv Ophthalmol. 2012 Sep;57(5):486-94. doi: 10.1016/j.survophthal.2011.06.004. Epub 2011 Oct 21.

PMID:
22018675
47.

Candida dubliniensis endophthalmitis in a HIV-infected intravenous drug abuser.

Pelegrín L, Mesquida M, Adán A, Cervera C, Bosch-Mestres J, Esteban-Redondo C, Juiz-González P, Llorenç V, Miró JM.

Mycoses. 2011 Nov;54(6):e856-8. doi: 10.1111/j.1439-0507.2010.02000.x. Epub 2011 Sep 19. No abstract available.

PMID:
21929732
48.

[Vitrectomy surgery for the treatment of the vitreo-retinal complications of the pars planitis].

Molina-Prat N, Adán AM, Mesquida M, Pelegrini L, Rey A, Alvarez G.

Arch Soc Esp Oftalmol. 2010 Oct;85(10):333-6. doi: 10.1016/j.oftal.2010.07.003. Epub 2010 Nov 9. Spanish.

PMID:
21168058
49.

Oxaliplatin-Related Ocular Toxicity.

Mesquida M, Sanchez-Dalmau B, Ortiz-Perez S, Pelegrín L, Molina-Fernandez JJ, Figueras-Roca M, Casaroli-Marano R, Adán A.

Case Rep Oncol. 2010 Nov 22;3(3):423-427.

50.

What factors have influence on persistence of neck pain after a whiplash?

Cobo EP, Mesquida ME, Fanegas EP, Atanasio EM, Pastor MB, Pont CP, Prieto CM, Gómez GR, Cano LG.

Spine (Phila Pa 1976). 2010 Apr 20;35(9):E338-43. doi: 10.1097/BRS.0b013e3181c9b075.

PMID:
20375773

Supplemental Content

Loading ...
Support Center